Other · developed by Recursion Pharmaceuticals
REC-3964 is a drug studied in recurrent Clostridioides difficile infection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06536465 | Phase 2 | Recurrent Clostridioides Difficile Infection | Terminated | RXRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Recurrent Clostridioides Difficile Infection
Updated Nov 1, 2026. Something wrong or missing? Report it on the RXRX page.
See RXRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RXRX catalysts and pipeline →